December 17, 2017 6:27 AM ET

Biotechnology

Company Overview of Editas Medicine, Inc.

Company Overview

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome ed...

11 Hurley Street

Cambridge, MA 02142

United States

Founded in 2013

89 Employees

Phone:

617-401-9000

Key Executives for Editas Medicine, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $450.0K
Chief Financial Officer
Age: 43
Total Annual Compensation: $157.5K
Chief Medical Officer
Age: 58
Total Annual Compensation: $100.0K
Chief Scientific Officer
Age: 59
Total Annual Compensation: $136.5K
Compensation as of Fiscal Year 2016.

Editas Medicine, Inc. Key Developments

Editas Medicine, Inc. Announces Results from Experiments to Demonstrate Expanded CRISPR Genome Editing Strategies in Hematopoietic Stem Cells for the Treatment of Hematologic Diseases

Editas Medicine, Inc. announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of hematologic diseases such as sickle cell disease and beta-thalassemia. In these proof of concept experiments, the company demonstrated CRISPR/Cas9 homology directed repair (HDR) and CRISPR/Cpf1-directed editing in human CD34+ cells. The company reported these data in a poster presentation at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta. In experiments, CRISPR/Cas9 caused efficient and reproducible HDR in CD34+ cells with minimal impact on cell viability. In separate studies, CRISPR/Cpf1 efficiently edited at multiple sites, including targets associated with hereditary persistence of fetal hemoglobin (HPFH). These results confirm that Cpf1-directed editing expands the number of genomic sites accessible to develop genome editing medicines.

Editas Medicine Eyes Acquisitions

Editas Medicine, Inc. (NasdaqGS:EDIT) is looking for acquisitions. Editas Medicine raised $50 million in public offering of shares and intends to use the net proceeds for general corporate purposes may include, without limitation, research and development expenditures, the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.

Editas Medicine, Inc. Presents at 13th Annual Personalized Medicine Conference, Nov-15-2017 01:00 PM

Editas Medicine, Inc. Presents at 13th Annual Personalized Medicine Conference, Nov-15-2017 01:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Katrine S. Bosley, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Editas Medicine, Inc., please visit www.editasmedicine.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.